30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
Antigen presentation by tumor infiltrating B cells influences CD4 T cell phenotype and function in primary lung cancer patient tumors
Journal for ImmunoTherapy of Cancer volume 3, Article number: P397 (2015)
Despite improvements in surgical techniques and combined chemotherapies, the 5-year survival rate for all stages of non-small cell lung cancer (NSCLC) is only 18%. Understanding the function of tumor infiltrating lymphocytes (TILs) in NSCLC patient tumors will contribute to the development of rationally designed treatments and improved statistics. B cells in tumors (TIL-Bs) are detected in non-small cell lung cancer (NSCLC) and their frequency correlates with improved survival, however, the functional mechanism of TIL-Bs in solid tumors is not well understood. We hypothesize that TIL-Bs help generate potent, long-term immune responses against cancer by presenting tumor antigens to CD4 tumor infiltrating lymphocytes (TILs) in primary human lung tumors.
Using un-manipulated, primary human B cells from fresh tumor, tumor-adjacent, and normal (cancer-free) lung tissue per the protocol described in Figure 1, we observed that the total number of B cells at the site of the tumor versus the tumor-adjacent tissue was increased compared to other immune subsets (Figure 2). Further, in analyzing B cell markers of activation and exhaustion, we observed a spectrum of activation of TIL-Bs (Figure 2). Finally, we demonstrated that TIL-Bs present autologous tumor antigens (particularly the cancer-testis antigen XAGE-1b) to CD4 TILs in a subset of NSCLC patients; if the TIL-Bs were activated (CD69+CD27+CD21+) they polarized the CD4 TILs to T helper (anti-tumor) CD4 T cells and if the TIL-Bs were exhausted (CD69-CD27-CD21-CD95+) they polarized the CD4 TILs to T regulatory cells (pro-tumor) (Figure 3 and Figure 4). These data suggest that TIL-Bs polarize the phenotype and function of CD4 TILs in NSCLC patient tumors.
In conclusion, TIL-Bs can have dual function in NSCLC patient tumors, and determining if the TIL-Bs are activated or exhausted will allow appropriate stimulation of the anti-tumor function of TIL-Bs in NSCLC patients. Ultimately, results from this study will help predict how to target TIL-B functions in future TIL-B-specific immunotherapies or in combination with current immunotherapies for NSCLC patients like blockade of the inhibitory receptor, PD-1.
About this article
Cite this article
Bruno, T., Ebner, P., Moore, B. et al. Antigen presentation by tumor infiltrating B cells influences CD4 T cell phenotype and function in primary lung cancer patient tumors. j. immunotherapy cancer 3 (Suppl 2), P397 (2015). https://doi.org/10.1186/2051-1426-3-S2-P397
- NSCLC Patient
- Tumor Antigen
- Tumor Infiltrate Lymphocyte
- Primary Lung Cancer
- Human Lung Tumor